{"id":1274,"date":"2019-08-06T19:50:25","date_gmt":"2019-08-06T11:50:25","guid":{"rendered":"http:\/\/www.bioactivescreeninglibrary.com\/?p=1274"},"modified":"2022-01-07T10:53:59","modified_gmt":"2022-01-07T02:53:59","slug":"carcinogenesis-multistep-process-defined-uncontrolled-cell-growth-neoplastic-progression-leading-invasive","status":"publish","type":"post","link":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2019\/08\/06\/carcinogenesis-multistep-process-defined-uncontrolled-cell-growth-neoplastic-progression-leading-invasive\/","title":{"rendered":"Carcinogenesis is a multistep process defined by uncontrolled cell growth and neoplastic progression leading to invasive"},"content":{"rendered":"<p>The pattern of brain c-Fos induction after C75 treatment is also consistent with visceral illness. Systemic injection of 10 or 30 mg\/kg C75 induces intensive c-Fos activation in the PVN and the nucleus tractus solitarius\/area postrema 1-2 h after the injection. Similarly, ip injection of malaise-inducing doses of LiCl causes c-fos activation in the hypothalamic PVN and in the brainstem NTS. Systemic injection of C75 produces conditioned taste aversion further supporting the notion of visceral illness. In agreement with previous reports, there was no difference in the baseline energy expenditure or RER between ghrelin receptor KO and WT mice. Systemic bolus injection of C75 suppressed energy expenditure as reported earlier and also decreased RER. There was no difference in these <a href=\"http:\/\/www.abmole.com\/products\/r428.html\">R428<\/a> responses between the two genotypes indicating that ghrelin signaling is not required for the metabolic actions of C75. Suppressed energy expenditure and RER are consistent with the state of energy conservation and a shift to lipid catabolism, typical metabolic responses to fasting. It is likely that these responses to C75 are also secondary to suppressed feeding. The strong correlation between the time course of the anorectic effect and the suppression of energy expenditure further support this notion. In one study, but not in others, C75 treated animals lost more weight than the pair-fed controls leading to the speculation that C75 has an additional, direct energy expenditure-stimulating effect. The observation, however, that the treatment causes diarrhea leads to an alternative explanation for the increased weight loss after C75 administration. C75 is a potent inhibitor of FAS in vitro. It has been proposed that weight loss-inducing and food intake-suppressive effects of C75 are related to the suppression of FAS activity in the hypothalamus. According to this hypothesis, FAS inhibition-induced increases in malonyl-CoA in hypothalamic neurons <a href=\"http:\/\/www.abmole.com\/products\/pci-32765.html\">PCI-32765 936563-96-1<\/a> provide a signal that leads to the activation of feeding-suppressive mechanisms. The efficiency of systemic C75 treatment to suppress brain FAS activity is, however, questionable. Systemic injection of 30 mg\/kg C75 does not affect hypothalamic FAS enzyme activity, therefore it can be ruled out that the observed sleep, activity, body temperature and metabolic effects observed in our experiments are related to the inhibition of FAS activity in the brain. Furthermore, the plasma levels of C75 after administering 10 or 30 mg\/kg ip reach less than 1% of the concentration needed for FAS inhibition in vitro. C75, however, has significant anorectic, motor activity-inhibiting and metabolic effect in this dose range suggesting that these actions are unrelated to the inhibition of brain FAS. The most parsimonious explanation for the observed actions is that they are due to the aversive actions of C75. As a result of visceral illness, feeding and motor activity are suppressed. Decreased eating and activity lead to suppressed energy expenditure with the concomitant decrease in body temperature and to the shift from carbohydrate to lipid utilization manifested as decreased RER. The disrupted sleep pattern <img src=\"http:\/\/www.abmole.com\/upload\/structure\/Zibotentan-ZD4054-chemical-structure.gif\" align=\"right\" width=\"204\" style=\"padding:10px;\"\/>likely reflects the aversive effects. Since C75 has sparked interest for its potential use in body weight reduction and cancer therapy, its effects on sleep, activity and metabolism need to be considered also in this context. In conclusion, we demonstrated that systemic injection of C75 induces long-lasting decreases in sleep, motor activity, feeding, VO2 and RER. It is unlikely that these actions are due to the effects of C75 on brain FAS or the ghrelin system.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The pattern of brain c-Fos induction after C75 treatment is also consistent with visceral illness. Systemic injection of 10 or 30 mg\/kg C75 induces intensive c-Fos activation in the PVN and the nucleus tractus solitarius\/area postrema 1-2 h after the injection. Similarly, ip injection of malaise-inducing doses of LiCl causes c-fos activation in the hypothalamic &hellip; <a href=\"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2019\/08\/06\/carcinogenesis-multistep-process-defined-uncontrolled-cell-growth-neoplastic-progression-leading-invasive\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Carcinogenesis is a multistep process defined by uncontrolled cell growth and neoplastic progression leading to invasive&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1274"}],"collection":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=1274"}],"version-history":[{"count":1,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1274\/revisions"}],"predecessor-version":[{"id":1275,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1274\/revisions\/1275"}],"wp:attachment":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=1274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=1274"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=1274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}